Table 1.
EUBD (n = 18) | |
---|---|
Sex, male/female, ratio (%) | 11/7 (61.1) |
Age (years), mean (SD) | 68.8 (16.4) |
median (range) | 74 (35.4–94.4) |
WHO status, mean (SD) | 2.1 (0.5) |
Cancer primary: | |
Pancreatic adenocarcinoma, n (%) | 8 (44.4) |
Hilar cholangiocarcinoma, n (%) | 5 (27.8) |
Colorectal adenocarcinoma, n (%) | 3 (16.7) |
Gastric adenocarcinoma,n (%) | 2 (11.1) |
Ascites, n (%) | 5 (27.8) |
Septic cholangitis, n (%) | 9 (50) |
Total bilirubin, mean (SD), mg/dl | 12.2 (7.3) |
Hilar obstruction, n (%) | |
Local recurrence | 6 (33.3) |
Hepatic metastases | 4 (22.2) |
Pancreatic mass | 3 (16.7) |
Hilar cholangiocarcinoma | 3 (16.7) |
Peritoneal carcinomatosis nodule | 2 (7.1) |
Reasons for failure or preclusion of transpapillary drainage (%) | |
Surgically modified anatomy | 10 (55.6) |
Impassable stricture at ERCP | 7 (38.9) |
Duodenal obstruction | 1 (5.6) |
Bismuth Classificationa | |
I–II | 7 (47.7) |
III | 7 (47.7) |
IV | 1 (6.7) |
Exclusion of three patients who presented unclassable hilar stenosis (hepatic surgery) in the Bismuth Classification.